Status:
TERMINATED
Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a pilot study. A pilot study is done with a small number of participants to see if a technique works before using it in a larger research study. This pilot study is evaluating a special kind o...
Detailed Description
If you agree to participate in this research study you will be asked to undergo some screening tests or procedures to find out if you can be in the research study. Many of these tests and procedures a...
Eligibility Criteria
Inclusion
- Histologically confirmed non-small cell lung cancer
- Tumor between 1 cm and 6 cm
- No evidence of nodal involvement or distant metastases
- Deemed to be a candidate for stereotactic body radiation therapy for NSCLC
- Able to lie still during DCE-MRI (up to 60 minutes)
- Adequate renal function to tolerate intravenous gadolinium contrast injection
Exclusion
- Prior thoracic radiotherapy or surgery
- Implanted pacemaker or cardiac defibrillator
- Contraindications to undergoing MRI
- Uncontrolled intercurrent illness
- Pregnant or breastfeeding
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01799135
Start Date
November 1 2012
End Date
February 1 2021
Last Update
October 12 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215